Captor Therapeutics

Captor Therapeutics leverages its proprietary Optigrade™ platform to discover and develop novel therapeutics based on Targeted Protein Degradation (TPD), a revolutionary approach to address high unmet medical needs. The company, with R&D labs in Wroclaw, Poland, and business operations in Basel, Switzerland, has secured over €76 million in non-dilutive grant funding for its R&D projects. Its pipeline includes a first-in-class MCL-1 degrader for resistant cancers and programs in colorectal cancer and autoimmune diseases, positioning it as a key European player in the competitive TPD field.

The Optigrade™ platform is a proprietary Targeted Protein Degradation (TPD) engine that discovers and optimizes novel bifunctional degraders (PROTACs) and molecular glues, with a focus on expanding the toolbox of E3 ubiquitin ligases to enable selective degradation of 'undruggable' targets.

1 drug in pipeline

Captor competes in the global TPD arena against clinical-stage leaders like Arvinas, Kymera, and Nurix, as well as large pharma internal efforts. Its differentiation lies in its cost-effective Polish R&D base, substantial non-dilutive grant funding, and a platform strategy focused on discovering novel E3 ligases to overcome limitations of current TPD approaches.